JM FINN

Coleman Street Investments

Growth Portfolio

31 March 2021

Investment objective


To seek a combination of long-term capital appreciation and income, but with a focus on growth, with a medium risk investment profile.

Benchmark

The Fund is benchmarked against the MSCI PIMFA Growth Index (Total Return) and will take active positions relative to this index on both asset allocation and stock selection. The Fund's broad asset allocation (split by equities, fixed income and alternatives) will typically be restricted to a range, relative to the benchmark, set by the CSI Investment Committee.

On 1 March 2017 the WMA (now PIMFA) range of Private Investor comparators replaced FTSE International with indices provided by MSCI and IHS Markit.

Asset allocation



Investment policy

In order to achieve its objective, the Fund will invest principally in a diversified portfolio of different asset classes such as equities, equity linked securities (including warrants and convertible securities), fixed and floating rate debt securities, index linked bonds, cash and cash equivalents. Equities will be the dominant asset class.

The equity part of the Fund's portfolio will contain primarily securities from the leading UK companies (FTSE 350) or their equivalents from overseas markets. The equity part of the portfolio may also consist of, but to a proportionately lesser extent, the securities of smaller companies. The bond part of the Fund's portfolio will contain mainly bonds such as sovereign debt or securities guaranteed by governments and corporate debt with the focus being on medium to high credit quality. The bond part of the portfolio may also consist of, but to a proportionately lesser extent, lower quality bonds.

Key information

Benchmark: MSCI PIMFA Growth Index Unit Price (1 Acc Shares) Dividend Yield* Dividend Payment (month end) Inception	£1.62 0.0% Jan & Jul 15-Apr-13
Fees:	
Class 1 Shares	
Ongoing Charges* *	0.61%
Transaction Costs	0.31%
Total cost of Ownership	0.92%
Performance Fee	n/a
Exit Charge	n/a
Accumulation shares SEDOL	B9LCQ87
Accumulation shares ISIN	LU0904709903
Fund Manager (since 26/07/19)	James Godrich, CFA
Deputy Fund Manager (since 01/07/20)	Christopher Barrett

Top 10 direct holdings

		Percentage
1	JP MORGAN CHASE & CO	2.5%
2	BERKSHIRE HATHAWAY INC	2.4%
3	PAYPAL INC	2.2%
4	JOHNSON & JOHNSON COM	2.0%
5	HARGREAVES LANSDOWN	1.6%
6	UNILEVER	1.6%
7	CLOSE BROS	1.6%
8	RELX	1.6%
9	BURBERRY GROUP	1.5%
10	COOPER COS	1.4%

Top 10 fund holdings

		Percentage
1	VANGUARD S&P 500 ETF	7.9%
2	HSBCS&P500 ETF	6.5%
3	PACIFIC ASSETS TRUST	4.6%
4	PRUSIK ASIA	4.0%
5	ARTEMIS FUND MGRS EUROPEAN OPPORTUNITIES	3.5%
6	SCOTTISHMORGAGEINVTRUST	3.5%
7	BAILLIE GIFFORD JAPAN TRUST	2.8%
8	EUROPEAN OPPS TRUST	2.3%
9	TWENTYFOUR ABSOLUTE RETURN CREDIT	2.0%
10	PERSONALASSETS TRUST	2.0%



Dorooptog



Powering financial insight

1

JM Finn

Dereenteer

Cumulative performance

(% total return)

	3m	6m	1yr	3yr	5yr
CSI Growth	2.1%	10.5%	31.8%	31.4%	59.7%
MSCI PIMFA Growth	3.2%	11.9%	27.0%	23.5%	54.4%

Source: Cadelam and Factset

Past performance is not a reliable indicator of future results.

All performance figures shown are net of underlying fund charges.

*The yield reflects historic distributions declared over the past twelve months as a percentage of the mid-market unit price, as at the date shown and after the deduction of the funds expenses.

**Ongoing charge represents the direct costs of running a fund, which are deducted from the assets of the fund and provide a comparable number for the cost of investing. The annual management charge is included in the ongoing charge.

Fund manager commentary

During the first quarter, the Fund returned 2.10%, against the PIMFA Growth Index that returned 3.18%. Relative underperformance was driven by stock selection within our UK equities.

At the end of the first quarter the UK became the fourth country behind Israel, the UAE and Chile to have administered more than 50 vaccination doses per 100 people in its population. As this remarkable progress is made we hope that the Covid 19 pandemic will no longer be front and centre of our market commentary.

It is right to reflect upon the last year as one of many challenges, sadness and difficulty but perhaps it is also right, at this point, to look forward and concentrate on the positive outcomes and the opportunities that have been created. It appears that in 2021, financial markets certainly began the process of the latter and the dominant themes in the quarter were of relief, optimism and hope often described by commentators as a backdrop of 'reflation'.

That same sentiment can be seen in the performance of the underlying stocks within the funds over the quarter with tailwinds coming from cyclically exposed businesses such as **Close Brothers** and **Electrocomponents**, offset by headwinds from defensive businesses such as **Unilever** and **Experian**.

Over the last 18 months we have steadily increased our exposure to cyclical businesses in the funds and took another step in that direction in the quarter with a new holding in arguably the UK's best retailer in **Next.**

Whilst so many of their peers have suffered and fallen, Next have been able to deliver consistent and impressive returns to shareholders. Excluding special dividends (of which there have been a number) and pre Coronavirus, dividends had compounded at 5.0% per year over the most recent 5 years and 11.6% per year over the most recent 10 years. The business was able to grow and survive in an incredibly challenging 15 year period. As supply is now falling rapidly out of the market and demand appears strongly pent up we hope that Next is a business that can now grow and thrive over the next 15 years.

The question on the lips of investors now is whether continued optimism causes further outperformance of cyclically exposed businesses or whether a cautious consumer means a pause for breath and a return to strength for defensive earnings. Through a diversified portfolio of exceptional businesses we don't think it is necessary to decide. Indeed, we prefer to follow the words of Nobel Prize winning economist, Harry Markowitz when he said that 'diversification is the only free lunch in investing' – as the pubs, bars and restaurants re-open in the UK, perhaps now is exactly the right time to tuck in!

Important information

Past performance is not a reliable indicator of future results. All performance figures shown are net of underlying fund charges. The value of CSI Growth may go down as well as up and you may not receive back all the money you invest. Investment should be made on the basis of the Prospectus and Key Investor Information Document (KIID), available on our website. You should seek professional advice as to the suitability of the Fund before investing. Values may be affected by fluctuations in exchange rates where assets in the Fund are denominated in currencies other than sterling.

Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

The information in this document does not constitute advice or a recommendation and you should not make any investment decisions on the basis of it. This document is for the information of the recipient only and should not be reproduced, copied or made available to others.

The fund is a Luxembourg domiciled open-ended investment company (SICAV) which is an EEA UCITS fund. The Management Company of the SICAV is Cadelux S.A., the Depositary, Administrative, Corporate and Domiciliary agent, Registrar and Transfer Agent is Delen Private Bank. JM Finn is the Investment Manager as appointed by Cadelux S.A. This Fund is not offered, sold or distributed in the United States or to US persons.

JM Finn and JM Finn & Co are trading names of J.M. Finn & Co. Ltd which is registered in England with number 05772581. Authorised and regulated by the Financial Conduct Authority.

Registered Office:+44 (0) 20 7600 16604 Coleman Streetinfo@jmfinn.comLondon, EC2R 5TAwww.jmfinn.com2

Discrete 12 month performance

(% total return)

					(
		31.03.17 31.03.16	31.03.18 31.03.17	31.03.19 31.03.18	31.03.20 31.03.19	31.03.21 31.03.20
	CSI Growth	17.6%	3.4%	8.3%	-8.0%	31.8%
-	MSCI PIMFA Growth	22.5%	2.1%	7.6%	-9.5%	27.0%

+Please note that the PIMFA performance data included is blended to reflect the

FTSE WMA Series up to 1 March 2017 and the PIMFA MSCI Series thereafter.